Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development
This agreement is expected to ensure Good Manufacturing Practice (GMP)-compliant drug product supply ahead of the planned Phase IIb clinical trials which the Company expects to start next year. The collaboration marks an important milestone for Oragenics as it secures domestic production capabilities to support its upcoming clinical and regulatory efforts.
'We are excited to partner with Sterling's facility in Cary, North Carolina, to support the production of ONP-002,' said Janet Huffman, Chief Executive Officer of Oragenics. 'This partnership is a critical milestone in our path forward for Phase IIb clinical trials. This partnership reinforces our commitment to quality, efficiency, and U.S.-based innovation and we believe this step will help streamline our clinical development strategy.'
Sterling will produce ONP-002 under strict cGMP conditions for use in Oragenics' planned Phase IIb trials, a proof-of-concept study which will evaluate early efficacy of ONP-002 in patients with mild traumatic brain injury (mTBI).
Chad Telgenhof, Chief Commercial Officer at Sterling Pharma Solutions, said: 'We are pleased to be partnering with Oragenics for the GMP production of its lead molecule for clinical trials. Our scientific expertise in CNS therapies and our ability to meet critical timelines will support the continued path to market for this transformative drug candidate.'
This U.S.-based manufacturing agreement builds upon Oragenics' broader strategy to develop scalable, accessible, and fast-acting treatments for neurological trauma, beginning with concussion, a condition that currently has no FDA-approved pharmacological therapies.
About Oragenics, Inc. Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders. Its lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. The Company's intranasal delivery technology is designed to deliver fast, targeted, and non-invasive therapy to the brain. For more information, please visit www.oragenics.com.
About Sterling Pharma SolutionsSterling Pharma Solutions is a global contract development and manufacturing organization (CDMO) with more than 50 years' experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specializing in handling challenging chemistries. Sterling manages the most complex API challenges from proof-of-concept to commercial manufacture, as well as antibody-drug conjugate (ADC) research and development bioconjugation services.
Sterling has six facilities employing more than 1,350 people: its HQ in Dudley, Cramlington, UK and a site in Newcastle upon Tyne, UK; a European presence in Ringaskiddy, Co. Cork, Ireland; a dedicated bioconjugation and ADCs facility in Deeside, North Wales, UK; and two sites in the US, in Cary, North Carolina and Germantown, Wisconsin. Find out more at www.sterlingpharmasolutions.com.
Forward-Looking Statements
This communication contains 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's beliefs and assumptions and information currently available. The words 'believe,' 'expect,' 'anticipate,' 'intend,' 'estimate,' 'project' and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.
Oragenics, Inc.Janet HuffmanChief Executive Officer813-286-7900jhuffman@oragenics.com
Investor Contact:Rich CockrellCG Capital866.889.1972ogen@cg.capital
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
CoStar Group, Inc. (CSGP): A Bull Case Theory
We came across a bullish thesis on CoStar Group, Inc. on Andvari's Substack by Douglas Ott. In this article, we will summarize the bulls' thesis on CSGP. CoStar Group, Inc.'s share was trading at $92.96 as of July 24th. CSGP's trailing and forward P/E were 357.54 and 222.22 respectively according to Yahoo Finance. An elegant residential building set against the modern skyline. CoStar Group reported another quarter of strong performance in Q2 2025, marking its 57th consecutive quarter of double-digit revenue growth with sales up 15% year over year and all-time high net new bookings of $93 million. Adjusted EBITDA rose 108% to $85 million, and membership surged 56% sequentially. Despite a slight dip in gross margins from the February addition of Matterport, operational restructuring is underway, including eliminating unprofitable units and expanding its salesforce. remains the centerpiece of CoStar's strategy, with a dedicated and growing sales team driving subscription adoption, improved agent Net Promoter Scores rising from 4 to 38 over three quarters, and marketing investments stabilizing monthly active users. Regulatory and legal pressures on competitors create tailwinds: in the U.S., Zillow faces an antitrust lawsuit from Compass over restrictive listing practices, enabling CoStar to boost profile by offering free advertising to banned listings; and in Australia, REA Group, dominant in the market, faces an antitrust investigation amid steep agent fee hikes, coinciding with CoStar's planned acquisition of challenger portal Domain. Additional uncertainty arises from potential leadership reshuffling within REA and U.S.-based both owned by the Murdoch family, which could further benefit Domain. With targeting an expansion of its salesforce from 230 to 750 by year-end and a stabilizing user base, CoStar appears increasingly well-positioned to challenge entrenched incumbents like Zillow and REA. Supported by operational momentum, strategic acquisitions, and heightened competitive scrutiny, CoStar's residential portals hold growing potential to emerge as true category leaders rather than cash-intensive experiments. Previously we covered a on CoStar Group, Inc. (CSGP) by Douglas Ott in February 2025, which highlighted CoStar's aggressive expansion of its strong financial base, and potential for margin recovery as investments scale. The company's stock price has appreciated about 20% since our coverage. The thesis still stands as execution remains robust. Douglas Ott shares a similar view but emphasizes regulatory tailwinds and operational gains. CoStar Group, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held CSGP at the end of the first quarter which was 56 in the previous quarter. While we acknowledge the potential of CSGP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Sign in to access your portfolio
Yahoo
12 minutes ago
- Yahoo
Amberton University Completes Major Overhaul, Revamping 100% of Courses and Expanding Programs
New initiatives include innovative AI integration, career-focused curriculum, and expanded healthcare and business programs. Garland, Texas--(Newsfile Corp. - July 25, 2025) - Amberton University announced today the completion of a comprehensive overhaul, revamping all courses and significantly expanding its program offerings for the 2025-2026 academic year. To view an enhanced version of this graphic, please visit: This initiative includes innovative AI integration, a highly career-focused curriculum, and expanded healthcare and business programs. "All Amberton courses have been completely updated with modern, real-world skills and AI competencies," stated Dr. Carol A. Palmer, President of Amberton University. Established over 50 years ago, Amberton University is renowned for its affordable, flexible education tailored specifically for working adults. Major Curriculum Overhaul Amberton has updated every course offered, clearly defining industry-driven skills across key programs such as project management, finance, clinical mental health counseling, and school counseling. This strategic initiative enhances graduates' career readiness and significantly boosts their practical value to employers. A Leader in AI Literacy Amberton is among the first fully AI-literate campuses nationwide, integrating AI competencies into every course. Business courses emphasize AI-driven strategies, Finance courses incorporate AI-based financial analysis, and Counseling courses explore AI-assisted therapeutic interventions. The newly launched Master of Science in Applied Artificial Intelligence program emphasizes responsible and strategic AI implementation. Students gain practical, hands-on learning experiences through an interactive AI Testing Environment, building tangible portfolios that demonstrate their AI proficiency. New Degree Programs and Certificates Amberton has introduced four critical new degree programs aligned with market demands: Master of Science in Applied Artificial Intelligence Master of Healthcare Administration (MHA) - This program is designed for individuals aiming to excel in executive and managerial positions within the healthcare sector. MBA in Finance - Focusing on fintech, cryptocurrency, blockchain, and advanced financial analytics. Master of Science in Training & Development - Addressing the increasing demand for workforce training and digital education. Additionally, nine practical certificate programs have been added as pathways toward full degrees, tailored to immediate industry needs. Commitment to Affordable, Quality Education Amberton maintains its position as one of the most affordable institutions nationwide, clearly outlining a transparent tuition model on its website. By avoiding unnecessary infrastructure costs, Amberton provides affordability without compromising educational quality. Faculty Voices and Industry Expertise Amberton faculty incorporate professional expertise directly into their instruction: Dr. Don Hebbard, Counseling: "Our students graduate ready to immediately make a difference, both professionally and personally." Dr. Deborah Hill, Human Development: "We're providing education that's immediately relevant to the workforce, not just theory." Dr. Ron Norris, Healthcare Administration: "Amberton's new healthcare program fills a critical need for qualified leaders in a rapidly growing healthcare sector." Dr. John Sinclair, AI Program Coordinator: "Amberton's AI curriculum uniquely positions graduates to become ethical, innovative leaders in AI implementation." Dr. Ken Johnson, Clinical Mental Health: "We remain highly responsive to student needs, continuously improving our counseling program to reflect current mental health practices." Student Success and Outcomes "This major overhaul is not just an update. It's Amberton's commitment to preparing our students for success in a rapidly changing world," stated Dr. Palmer. "Our students deserve an education that makes practical sense, and that's exactly what Amberton delivers." Interested students and professionals can apply easily and at no cost via the university's streamlined admission portal. Contact: Dr. Carol Anne PalmerUniversity Presidentpresident@ University To view the source version of this press release, please visit Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
12 minutes ago
- Yahoo
ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.
Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. ('Regional') (OTCBQ: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, announced today that leading independent proxy advisory firm Institutional Shareholder Services Inc. ('ISS') recommended that Regional shareholders vote 'FOR': (1) the approval of the Amended and Restated Agreement and Plan of Merger, dated April 14, 2025 (as amended, the 'Merger Agreement'), by and between Regional and SunLink Health Systems, Inc. (the 'Merger Proposal'), (2) the approval of the issuance of shares of Regional common stock and Regional Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares (the 'Regional Series D preferred stock') in connection with the merger (the 'Share Issuance Proposal'), and (3) the approval to adjourn the Regional special meeting to solicit additional proxies in favor of the Merger Proposal or the Share Issuance Proposal if there are insufficient votes at the time of such adjournment to approve the Merger Proposal or the Share Issuance Proposal. In its July 23, 2025 report, ISS noted:1 The strategic rationale for the merger appears sound considering the pre-tax cost synergies and enhanced possibility of long-term profitability. The outperformance of SunLink and Regional since announcement suggests that investors view the proposed combination favorably. Brent Morrison, CFA, Chairman and Chief Executive Officer of Regional, stated, 'Regional is pleased that ISS concluded that support for this transaction was warranted. Regional is even more pleased that, of the proxies received to date, approximately 80% of Regional's common stock shareholders see it the same way.' SPECIAL MEETING OF SHAREHOLDERSJuly 29, 2025 at 10 am ET YOUR VOTE IS IMPORTANT. VOTE TODAY! About Regional Health Properties Regional Health Properties, Inc., a Georgia corporation, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care. For more information, visit NO OFFER OR SOLICITATION Communications in this press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any proxy vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the 'Securities Act'). ADDITIONAL INFORMATION The proposed merger will be submitted to both the Regional and SunLink shareholders for their consideration. In connection with the proposed merger, Regional filed a Registration Statement on Form S-4 (File No. 333-286975) (the 'Registration Statement') with SEC that includes a joint proxy statement/prospectus for Regional and SunLink, which was sent to common stock shareholders of Regional and common stock shareholders of SunLink on or about June 30, 2025. INVESTORS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE CORRESPONDING JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED MERGER, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, TOGETHER WITH ALL AMENDMENTS AND SUPPLEMENTS TO THOSE DOCUMENTS, AS THEY WILL CONTAIN IMPORTANT INFORMATION. IN ADDITION, INVESTORS ARE URGED TO READ THE TENDER OFFER STATEMENT ON SCHEDULE TO FILED WITH THE SEC ON JULY 18, 2025 REGARDING A PROPOSED TENDER OFFER, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, TOGETHER WITH ALL AMENDMENTS AND SUPPLEMENTS TO THOSE DOCUMENTS, AS THEY WILL CONTAIN IMPORTANT INFORMATION. You are able to obtain a copy of the joint proxy statement/prospectus, as well as other filings containing information about Regional and SunLink, without charge, at the SEC's website ( or by accessing Regional's website ( under the tab 'Investor Relations' or by accessing SunLink's website ( under the tab 'Investors.' Copies of the joint proxy statement/prospectus can also be obtained, without charge, by directing a request to Investor Relations, Regional Health Properties, Inc., 1050 Crown Pointe Parkway, Suite 720, Atlanta, Georgia, 30338, telephone 678-869-5116 or to Investor Relations, SunLink Health Systems, Inc., 900 Circle 75 Parkway, Suite 690, Atlanta, Georgia, 30339, telephone 770-933-7004. Regional and SunLink and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Regional and SunLink in connection with the proposed merger. Information about the directors and executive officers of Regional is set forth in the proxy statement for Regional's Annual Report on Form 10-K for the year ended December 31, 2024 (the 'Regional Annual Report'), as filed with the SEC on March 31, 2025, which information may be updated by Regional from time to time in subsequent filings with the SEC. Information about the directors and executive officers of SunLink is set forth in the proxy statement for SunLink's Amendment No. 1 to Annual Report on Form 10-K/, as filed with the SEC on October 25, 2024, which information may be updated by SunLink from time to time in subsequent filings with the SEC. Additional information about the interests of those participants and other persons who may be deemed participants in the transaction may also be obtained by reading the joint proxy statement/prospectus relating to the proposed merger when it becomes available. Free copies of this document may be obtained as described above. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements can often, but not always, be identified by the use of words like 'believe', 'continue', 'pattern', 'estimate', 'project', 'intend', 'anticipate', 'expect' and similar expressions or future or conditional verbs such as 'will', 'would', 'should', 'could', 'might', 'can', 'may', or similar expressions. These forward-looking statements include, but are not limited to, statements relating to the expected benefits of the proposed merger between Regional and SunLink, including pre-tax cost synergies and profitability, other statements of expectations regarding the merger, and other statements of Regional's goals, intentions and expectations. These forward-looking statements are subject to significant risks, assumptions and uncertainties that may cause results to differ materially from those set forth in forward-looking statements, including, among other things: the risk that the businesses of Regional and SunLink will not be integrated successfully or such integration may be more difficult, time-consuming or costly than expected; expected revenue synergies and cost savings from the merger may not be fully realized or realized within the expected time frame; revenues following the merger may be lower than expected; customer, vendor and employee relationships and business operations may be disrupted by the merger; the ability to obtain required regulatory approvals or the approvals of Regional's or SunLink's shareholders, and the ability to complete the merger on the expected timeframe; the costs and effects of litigation and the possible unexpected or adverse outcomes of such litigation; the ability of Regional and SunLink to meet the initial or continued listing requirements or rules of the NYSE American LLC or the OTCQB, as applicable, and to maintain the listing or trading, as applicable, of securities thereon; possible changes in economic and business conditions; the impacts of epidemics, pandemics or other infectious disease outbreaks; the existence or exacerbation of general geopolitical instability and uncertainty; possible changes in monetary and fiscal policies, and laws and regulations; competitive factors in the healthcare industry; Regional's dependence on the operating success of its operators; the amount of, and Regional's ability to service, its indebtedness; covenants in Regional's debt agreements that may restrict its ability to make investments, incur additional indebtedness and refinance indebtedness on favorable terms; the effect of increasing healthcare regulation and enforcement on Regional's operators and the dependence of Regional's operators on reimbursement from governmental and other third-party payors; the relatively illiquid nature of real estate investments; the impact of litigation and rising insurance costs on the business of Regional's operators; the effect of Regional's operators declaring bankruptcy, becoming insolvent or failing to pay rent as due; the ability of any of Regional's operators in bankruptcy to reject unexpired lease obligations and to impede its ability to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor's obligations; Regional's ability to find replacement operators and the impact of unforeseen costs in acquiring new properties; and other risks and factors identified in (i) Regional's cautionary language included under the headings 'Statement Regarding Forward-Looking Statements' and 'Risk Factors' in the Regional Annual Report, and other documents subsequently filed by Regional with the SEC and (ii) SunLink's cautionary language included under the headings 'Forward-Looking Statements' and 'Risk Factors' in SunLink's Annual Report on Form 10-K for the year ended June 30, 2024, and other documents subsequently filed by SunLink with the SEC. Neither Regional nor SunLink undertake any obligation to update any forward-looking statement, whether written or oral, relating to the matters discussed in this press release. In addition, Regional's and SunLink's past results of operations do not necessarily indicate either of their anticipated future results, whether the merger is effectuated or not. Regional ContactBrent Morrison, CFAChief Executive Officer & PresidentRegional Health Properties, (404) 1 Permission to cite ISS was neither sought nor obtained.
